Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

41. Heparin for the treatment of thrombosis in neonates.

Heparin for the treatment of thrombosis in neonates. BACKGROUND: Among pediatric patients, newborns are at highest risk of developing thromboembolism. Neonatal thromboembolic (TE) events may consist of both venous and arterial thromboses and often iatrogenic complications (eg, central catheterization). Treatment guidelines for pediatric patients with TE events most often are extrapolated from the literature regarding adults. Options for the management of neonatal TE events include expectant (...) management; nitroglycerin ointment; thrombolytic therapy or anticoagulant therapy, or a combination of the two; and surgery. Since the 1990s, low molecular weight heparin (LMWH) has become the neonatal anticoagulant of choice. Reasons for its appeal include predictable dose response, no need for venous access, and limited monitoring requirements. The overall major complication rate is around 5%. Whether preterm infants are at increased risk is unclear. No data are available on the frequency

Cochrane2016

42. Blood transfusion and filter set requirements with citrate anticoagulation compared with heparin in renal replacement therapy

Blood transfusion and filter set requirements with citrate anticoagulation compared with heparin in renal replacement therapy 28979523 2018 11 13 1751-1437 17 4 2016 Nov Journal of the Intensive Care Society J Intensive Care Soc Blood transfusion and filter set requirements with citrate anticoagulation compared with heparin in renal replacement therapy. 357 10.1177/1751143716647395 Taylor Nick N Department of Intensive Care, Royal Surrey County Hospital, Guildford, UK. Walter Edward E

Journal of the Intensive Care Society2016 Full Text: Link to full Text with Trip Pro

43. Five-year outcomes following a randomized trial of femorofemoral and femoropopliteal bypass grafting with heparin-bonded or standard polytetrafluoroethylene grafts

Five-year outcomes following a randomized trial of femorofemoral and femoropopliteal bypass grafting with heparin-bonded or standard polytetrafluoroethylene grafts 27477951 2016 08 24 2017 04 14 2017 04 14 1365-2168 103 10 2016 Sep The British journal of surgery Br J Surg Five-year outcomes following a randomized trial of femorofemoral and femoropopliteal bypass grafting with heparin-bonded or standard polytetrafluoroethylene grafts. 1300-5 10.1002/bjs.10246 Cohort studies suggest superior long (...) -term patency of luminal heparin-bonded polytetrafluoroethylene (Hb-PTFE) bypass grafts compared with standard PTFE grafts. The aim of this study was to compare the outcomes of Hb-PTFE grafts with those of standard PTFE grafts 5 years after a randomized trial. Patients with intermittent claudication or critical limb ischaemia requiring femorofemoral or femoropopliteal bypass grafting were randomized in a clinical trial of Hb-PTFE versus standard PTFE in 11 Scandinavian centres between 2005 and 2009

EvidenceUpdates2016

44. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial.

Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. OBJECTIVE: To test the optimal antithrombotic regimen in patients with acute coronary syndrome. DESIGN: Randomised controlled trial. SETTING: Patients with acute coronary syndrome with and without ST segment elevation in 78 centres in Italy, the Netherlands, Spain, and Sweden. PARTICIPANTS: 7213 patients with acute coronary (...) syndrome and planned percutaneous coronary intervention: 4010 with ST segment elevation and 3203 without ST segment elevation. The primary study results in the overall population have been reported previously. INTERVENTIONS: Patients were randomly assigned, in an open label fashion, to one of two regimens: bivalirudin with glycoprotein IIb/IIIa inhibitors restricted to procedural complications or heparin with or without glycoprotein IIb/IIIa inhibitors. MAIN OUTCOME MEASURES: Primary endpoints were

BMJ2016 Full Text: Link to full Text with Trip Pro

45. Intravenous heparin during ruptured abdominal aortic aneurysmal repair.

Intravenous heparin during ruptured abdominal aortic aneurysmal repair. BACKGROUND: There have been enormous advances in the screening, diagnosis, intervention and overall prognosis of abdominal aortic aneurysms (AAAs) in the last decade, but despite these, ruptured AAAs (rAAAs) still cause around 3500 to 6000 deaths in England and Wales each year. Open repair remains standard treatment for rAAA in most centres but increasingly endovascular aneurysm repair (EVAR) is being adopted. This has a 30 (...) -day postoperative mortality of 40%. This has remained static despite surgical, anaesthetic and critical care advances.One significant change to current practice for elective repairs of AAAs, as opposed to emergency repairs of rAAAs, has been the introduction of intravenous heparin. This provides a protective effect against cardiac and thrombotic disease in the postoperative period. This practice has not gained widespread acceptance for emergency repairs of rAAA even though a reduction in mortality

Cochrane2016

46. Increased unfractionated heparin requirements with decreasing body mass index in pregnancy

Increased unfractionated heparin requirements with decreasing body mass index in pregnancy 27829874 2018 11 13 1753-495X 9 4 2016 Dec Obstetric medicine Obstet Med Increased unfractionated heparin requirements with decreasing body mass index in pregnancy. 156-159 Pregnant women receiving low-molecular-weight heparin for therapeutic anticoagulation are often converted to unfractionated heparin in anticipation of labor. We aim to characterize the impact of maternal body mass index on attainment (...) of target anticoagulation during the conversion process. We conducted a five-year retrospective study of a pregnancy cohort converted from low-molecular-weight heparin to unfractionated heparin in the third trimester. Patient demographics, anticoagulation regimens, and clinical outcomes were extracted from the medical record. Nonparametric statistical methods were used for analysis by body mass index (<30, 30-35, and >35). Thirty-one subjects were evenly distributed by body mass index ( p = 0.97

Obstetric medicine2016 Full Text: Link to full Text with Trip Pro

47. The Effect of Extended Injection of Subcutaneous Heparin on Pain Intensity and Bruising Incidence

The Effect of Extended Injection of Subcutaneous Heparin on Pain Intensity and Bruising Incidence 27648193 2016 09 20 2018 11 13 2008-5842 8 7 2016 Jul Electronic physician Electron Physician The Effect of Extended Injection of Subcutaneous Heparin on Pain Intensity and Bruising Incidence. 2650-4 10.19082/2650 Reducing patients' pain is one of the main goals of providing clinical services, which requires nursing skill. As a simple technique, increasing the duration of subcutaneous heparin (...) injection may affect the intensity of pain and bruising. The aim of this study was to assess the effect of increasing the heparin injection time on pain intensity and bruising associated with subcutaneous injection. The present quasi-experimental study consisted of 86 patients, admitted to our hospital, who were treated with subcutaneous heparin injection. A McGill pain intensity questionnaire was used to measure pain severity in a purposive sampling. All of the subjects received subcutaneous heparin

Electronic physician2016 Full Text: Link to full Text with Trip Pro

48. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis

Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2016

49. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty

Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty 26790579 2016 02 29 2017 02 10 2017 02 10 0340-6245 115 3 2016 Mar Thrombosis and haemostasis Thromb. Haemost. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. 600-7 10.1160/TH15-07-0527 This prospective study was conducted to report the effect of oral factor Xa inhibitor (...) and low-molecular-weight heparin (LMWH) on surgical complications following total hip arthroplasty (THA). The patients with an age < 60 years were randomly assigned to three groups (rivaroxaban, enoxaparin, and placebo) and the patients with an age ≥ 60 years were assigned to two groups (rivaroxaban and enoxaparin). All drug regimens started at 12 hours postoperatively and continued for two weeks after surgery. Primary measure outcome was major surgical wound complications defined as haematoma requiring any intervention

EvidenceUpdates2016

50. Randomised controlled trial: Low-molecular-weight heparin for the treatment of acute venous thromboembolism in patients with active cancer

Randomised controlled trial: Low-molecular-weight heparin for the treatment of acute venous thromboembolism in patients with active cancer Low-molecular-weight heparin for the treatment of acute venous thromboembolism in patients with active cancer | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-molecular-weight heparin for the treatment of acute venous thromboembolism in patients with active cancer Article Text Therapeutics/Prevention Randomised controlled trial Low-molecular-weight heparin for the treatment of acute venous thromboembolism

Evidence-Based Medicine (Requires free registration)2016

51. Heparin for Maintaining Patency of Peripherally Inserted Central Catheters in Neonates: Evidence-Based Guidelines

Heparin for Maintaining Patency of Peripherally Inserted Central Catheters in Neonates: Evidence-Based Guidelines Heparin for Maintaining Patency of Peripherally Inserted Central Catheters in Neonates: Evidence-Based Guidelines | CADTH.ca Find the information you need Heparin for Maintaining Patency of Peripherally Inserted Central Catheters in Neonates: Evidence-Based Guidelines Heparin for Maintaining Patency of Peripherally Inserted Central Catheters in Neonates: Evidence-Based Guidelines (...) Published on: November 24, 2015 Project Number: RB0937-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What are the evidence-based guidelines regarding the appropriate dose of heparin required to maintain patency of peripherally inserted central catheters (PICC) for neonatal patients? Key Message No relevant literature was identified regarding the appropriate dose of heparin required to maintain patency of peripherally inserted central catheters

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

52. Heparin-Induced Thrombocytopenia.

Heparin-Induced Thrombocytopenia. Heparin-Induced Thrombocytopenia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26535525 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Nov 5;373(19):1883-4. doi: 10.1056/NEJMc1510993. Heparin-Induced Thrombocytopenia. . Comment on [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] PMID: 26535525 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full

NEJM2015 Full Text: Link to full Text with Trip Pro

53. Heparin-Induced Thrombocytopenia.

Heparin-Induced Thrombocytopenia. Heparin-Induced Thrombocytopenia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26535526 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Nov 5;373(19):1882-3. doi: 10.1056/NEJMc1510993#SA1. Heparin-Induced Thrombocytopenia. , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26535526 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You

NEJM2015 Full Text: Link to full Text with Trip Pro

54. Heparin-Induced Thrombocytopenia.

Heparin-Induced Thrombocytopenia. Heparin-Induced Thrombocytopenia. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26535527 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Nov 5;373(19):1883. doi: 10.1056/NEJMc1510993#SA2. Heparin-Induced Thrombocytopenia. . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 26535527 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here

NEJM2015 Full Text: Link to full Text with Trip Pro

55. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)

A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT) A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (...) and venous thromboembolism to a randomised controlled trial exploring the most effective way to manage CAT after 6 months’ anticoagulation therapy with low-molecular-weight heparin. {{author}} {{($index , , , , , , , , , , , , , , , & . Simon I Noble, 1 ,2 ,* Annmarie Nelson, 2 David Fitzmaurice, 3 Marie-Jet Bekkers, 4 Jessica Baillie, 5 Stephanie Sivell, 2 Joanna Canham, 1 Joanna D Smith, 1 Angela Casbard, 1 Ander Cohen, 6 David Cohen, 7 Jessica Evans, 1 Kate Fletcher, 8 Miriam Johnson, 9 Anthony

NIHR HTA programme2015

56. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.

Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. BACKGROUND: Conflicting evidence exists on the efficacy and safety of bivalirudin administered as part of percutaneous coronary intervention (PCI) in patients with an acute coronary syndrome. METHODS: We randomly assigned 7213 patients with an acute coronary syndrome for whom PCI was anticipated to receive either bivalirudin or unfractionated heparin. Patients in the bivalirudin group were subsequently randomly assigned (...) to receive or not to receive a post-PCI bivalirudin infusion. Primary outcomes for the comparison between bivalirudin and heparin were the occurrence of major adverse cardiovascular events (a composite of death, myocardial infarction, or stroke) and net adverse clinical events (a composite of major bleeding or a major adverse cardiovascular event). The primary outcome for the comparison of a post-PCI bivalirudin infusion with no post-PCI infusion was a composite of urgent target-vessel revascularization

NEJM2015 Full Text: Link to full Text with Trip Pro

57. Do you need to use heparin when initiating Coumadin therapy in a patient with atrial fibrillation?

Do you need to use heparin when initiating Coumadin therapy in a patient with atrial fibrillation? Do you need to use heparin when initiating Coumadin therapy in a patient with atrial fibrillation? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do you need to use heparin when initiating Coumadin therapy in a patient (...) with atrial fibrillation? View/ Open Date 2015-06 Format Metadata Abstract Do you need to use heparin when initiating Coumadin therapy in a patient with atrial fibrillation? Evidence-Based Answer: While the evidence is limited, current guidelines and biochemical studies suggest that it is probably not necessary to use heparin when initiating warfarin therapy in a patient with chronic stable atrial fibrillation (SOR: C, expert opinion and disease-oriented evidence). URI Part of Citation Evidence-based practice 18

Evidence Based Practice 2015

58. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme.

Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. 25938990 2015 05 05 2015 07 09 2016 03 02 1539-3704 162 9 2015 May 05 Annals of internal medicine Ann. Intern. Med. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. 601-9 10.7326/M14-2062 A daily injection of low-molecular-weight heparin (LMWH) is often (...) prescribed to women with unexplained recurrent pregnancy loss (RPL), although evidence suggesting a benefit is questionable. To determine whether LMWH increases ongoing pregnancy and live-birth rates in women with unexplained RPL. Controlled, multicenter trial with randomization using minimization conducted from 2006 to 2013. (ClinicalTrials.gov: NCT00400387). 14 university hospitals and perinatal care centers in Germany and Austria. 449 women with at least 2 consecutive early miscarriages or 1 late

Annals of Internal Medicine2015

59. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.

Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. IMPORTANCE: The safety and efficacy of bivalirudin compared with heparin with or without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI) are uncertain. OBJECTIVE: To determine if bivalirudin is superior to heparin alone and to heparin (...) plus tirofiban during primary PCI. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, open-label trial involving 2194 patients with AMI undergoing primary PCI at 82 centers in China between August 2012 and June 2013. INTERVENTIONS: Patients were randomly assigned to receive bivalirudin with a post-PCI infusion (n = 735), heparin alone (n = 729), or heparin plus tirofiban with a post-PCI infusion (n = 730). Among patients treated with bivalirudin, a postprocedure 1.75 mg/kg/h infusion was administered

JAMA2015

60. Association between perioperative low-molecular-weight heparin vs unfractionated heparin and clinical outcomes in patients with cancer undergoing surgery.

Association between perioperative low-molecular-weight heparin vs unfractionated heparin and clinical outcomes in patients with cancer undergoing surgery. CLINICAL QUESTION: In patients with cancer undergoing surgery, what is the association between perioperative thromboprophylaxis with low-molecular-weight heparin (LMWH) or unfractionated heparin and mortality, pulmonary embolism, deep venous thrombosis, thrombocytopenia, and bleeding outcomes? BOTTOM LINE: When used for perioperative (...) thromboprophylaxis, there are no differences in the association of LMWH vs unfractionated heparin for preventing mortality, pulmonary embolism, deep venous thrombosis, bleeding outcomes, or thrombocytopenia in patients with cancer.

JAMA2015